Logo image of TNG.PA

TRANSGENE SA (TNG.PA) Stock Fundamental Analysis

EPA:TNG - Euronext Paris - Matif - FR0005175080 - Common Stock - Currency: EUR

0.602  0 (0%)

Fundamental Rating

2

Taking everything into account, TNG scores 2 out of 10 in our fundamental rating. TNG was compared to 71 industry peers in the Biotechnology industry. TNG may be in some trouble as it scores bad on both profitability and health. TNG is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TNG has reported negative net income.
TNG had a negative operating cash flow in the past year.
TNG had negative earnings in each of the past 5 years.
In the past 5 years TNG always reported negative operating cash flow.
TNG.PA Yearly Net Income VS EBIT VS OCF VS FCFTNG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

TNG has a Return On Assets (-43.99%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -43.99%
ROE N/A
ROIC N/A
ROA(3y)-39.31%
ROA(5y)-30.88%
ROE(3y)-86.26%
ROE(5y)-64.34%
ROIC(3y)N/A
ROIC(5y)N/A
TNG.PA Yearly ROA, ROE, ROICTNG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TNG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNG.PA Yearly Profit, Operating, Gross MarginsTNG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

TNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNG has more shares outstanding
The number of shares outstanding for TNG has been increased compared to 5 years ago.
The debt/assets ratio for TNG has been reduced compared to a year ago.
TNG.PA Yearly Shares OutstandingTNG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
TNG.PA Yearly Total Debt VS Total AssetsTNG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.08, we must say that TNG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.08, TNG is not doing good in the industry: 63.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.08
ROIC/WACCN/A
WACC7.97%
TNG.PA Yearly LT Debt VS Equity VS FCFTNG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

TNG has a Current Ratio of 1.57. This is a normal value and indicates that TNG is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.57, TNG is not doing good in the industry: 60.56% of the companies in the same industry are doing better.
A Quick Ratio of 1.57 indicates that TNG should not have too much problems paying its short term obligations.
TNG has a Quick ratio (1.57) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.57
TNG.PA Yearly Current Assets VS Current LiabilitesTNG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.67% over the past year.
The Revenue for TNG has decreased by -23.68% in the past year. This is quite bad
The Revenue has been growing slightly by 1.51% on average over the past years.
EPS 1Y (TTM)32.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-23.68%
Revenue growth 3Y-6.51%
Revenue growth 5Y1.51%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TNG will show a small growth in Earnings Per Share. The EPS will grow by 2.42% on average per year.
The Revenue is expected to grow by 44.72% on average over the next years. This is a very strong growth
EPS Next Y28%
EPS Next 2Y46.52%
EPS Next 3Y0.88%
EPS Next 5Y2.42%
Revenue Next Year-44.69%
Revenue Next 2Y55.17%
Revenue Next 3Y-6.48%
Revenue Next 5Y44.72%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TNG.PA Yearly Revenue VS EstimatesTNG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
TNG.PA Yearly EPS VS EstimatesTNG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

TNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 10.84, the valuation of TNG can be described as very reasonable.
95.77% of the companies in the same industry are more expensive than TNG, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 20.44. TNG is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 10.84
TNG.PA Price Earnings VS Forward Price EarningsTNG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNG.PA Per share dataTNG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.52%
EPS Next 3Y0.88%

More info and screens

0

5. Dividend

5.1 Amount

TNG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSGENE SA

EPA:TNG (5/9/2025, 7:00:00 PM)

0.602

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-24 2025-04-24
Earnings (Next)09-16 2025-09-16
Inst Owners0.93%
Inst Owner ChangeN/A
Ins Owners0.7%
Ins Owner ChangeN/A
Market Cap79.64M
Analysts82.86
Price Target1.73 (187.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.84
P/S 10.43
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)0.06
Fwd EY9.23%
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.06
BVpS0
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.31%
ROA(5y)-30.88%
ROE(3y)-86.26%
ROE(5y)-64.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 237.06%
Cap/Sales 42.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.57
Altman-Z -4.08
F-Score3
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)95.02%
Cap/Depr(5y)109.94%
Cap/Sales(3y)17.95%
Cap/Sales(5y)15.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y28%
EPS Next 2Y46.52%
EPS Next 3Y0.88%
EPS Next 5Y2.42%
Revenue 1Y (TTM)-23.68%
Revenue growth 3Y-6.51%
Revenue growth 5Y1.51%
Sales Q2Q%N/A
Revenue Next Year-44.69%
Revenue Next 2Y55.17%
Revenue Next 3Y-6.48%
Revenue Next 5Y44.72%
EBIT growth 1Y-0.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.8%
EBIT Next 3Y-17.24%
EBIT Next 5Y-22.29%
FCF growth 1Y-157.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.79%
OCF growth 3YN/A
OCF growth 5YN/A